Embed Size (px)
Citation preview
Strides Pharma Science Limited CIN: L24230MH1990PLC057062
Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India Tel: +91 80 6784 0000 Fax: +91 80 6784 0700
Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942
[email protected]; www.strides.com
August 5, 2020 BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip code: 532531
The National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex Bandra (E) Mumbai - 400 051 Scrip code: STAR
Dear Sirs, Sub: Outcome of Board Meeting – Unaudited Financial Results (Standalone &
Consolidated) for the quarter ended June 30, 2020 We are pleased to enclose the Unaudited Financial Results (Standalone and Consolidated) of the Company along with Limited Review Report of the Statutory Auditors for the quarter ended June 30, 2020, as approved by the Board of Directors of the Company at their meeting held today, along with a press release issued in this regard. The board meeting commenced at 12:30 hrs and concluded at 13:20 hrs. This is for your information and record. Thanks & Regards,
For Strides Pharma Science Limited
Manjula Ramamurthy Company Secretary
Press Release
August 05, 2020
Strides reports a strong Q1FY21 performance
Bengaluru, India, August 05, 2020 - Strides Pharma Science Ltd (BSE: 532531, NSE: STAR) today announced its consolidated financial results for the quarter ended June 30, 2020 (Q1FY21)
PARTICULARS Q1FY21 QoQ% YoY%
Revenues ₹7,847m 26% 14%
Gross Margins ₹4,825m 29% 29%
EBITDA ₹1,578m 132% 27%
Pharma PAT ₹788m 839% 51%
Pharma EPS ₹8.8/share 839% 51%
Pharma PAT and Pharma EPS for Q1 FY21 represents the generic formulations business of the company. It excludes exceptional items gain of ₹445m and Biotech and CHC share of loss of ₹201m
Commenting on the performance, Dr R Ananthanarayanan, Managing Director & CEO, remarked, “Coming out of a challenging Q4 FY20 due to Ranitidine withdrawal, Strides has started FY21 on a positive note. We have reported strong performance across all our business in Q1 FY21 despite significant disruptions and ambiguity in the business environment due to Covid 19. Our regulated markets growth was 22% QoQ and our emerging markets are now returning to growth after several quarters. We have delivered healthy operating leverage that led to an 920bps QoQ EBITDA margin expansion with superior cash flows.
We are proud of our global workforce for their exemplary efforts to keep our operations running during the current crisis period. We continue to pursue a “People First” approach, and the wellbeing of our employees remains our top priority.
We have demonstrated resilience and agility to adapt to the current pandemic situation. While our manufacturing and supply chain continue to remain steady without any significant disruptions, we remain cautiously optimistic on the outlook of our business for the year as the operating environment continues to evolve.”
Detailed investor communication on the performance of the Company is attached
EARNINGS CALL WITH THE MANAGEMENT
Date:
Wednesday, August 5, 2020
Time:
5:15pm IST / 12:45pm BST / 07:45am EDT / 07:45pm HKT
Dial-in Details
Pre-Register to skip
operator and dial in https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=122333&linkSecurityString=5013968e
Dial in through operator
(India) +91 22 6280 1434 / +91 22 7115 8838/+91-7045671221
Other Countries
USA- 18667462133
UK-08081011573
Singapore-8001012045
Hongkong-800964448
Playback Recording +912271945757 / +912266635757 Playback Code: 66583
About Strides Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi) and the United States (Florida). The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com For further information, please contact:
Strides Badree Komandur Executive Director & CFO +91 80 6784 0747 Investor Relations: Sandeep Baid: +91 80 6784 0791 Email: [email protected] Strides Pharma Science Limited CIN: L24230MH1990PLC057062 Regd. Office: 201, ‘Devavrata’, Sector - 17, Vashi, Navi Mumbai - 400 703 Corp. Office: Strides House, Bannerghatta Road, Bangalore – 560076
Corporate Communication Dr Usha Iyer: +91 9987444106 Email: [email protected] PR Consultancy Fortuna PR K Srinivas Reddy: +91 90005 27213 [email protected] K Priya: +91 95354 25418 [email protected]
Q1FY21 EarningsAugust 05, 2020
2
A strong bounce back for Strides in Q1FY21 post ranitidine withdrawal
2
Coming out of a challenging Q4 FY20 due to Ranitidine withdrawal, Strides has started FY21
on a positive note. We have reported strong performance across all our business in Q1 FY21
despite significant disruptions and ambiguity in the business environment due to Covid 19.
Our regulated markets growth was 22% QoQ and our emerging markets are now returning to
growth after several quarters. We have delivered healthy operating leverage that led to an
920bps QoQ EBITDA margin expansion with superior cash flows.
We are proud of our global workforce for their exemplary efforts to keep our operations
running during the current crisis period. We continue to pursue a “People First” approach, and
the wellbeing of our employees remains our top priority.
We have demonstrated resilience and agility to adapt to the current pandemic situation.
While our manufacturing and supply chain continue to remain steady without any significant
disruptions, we remain cautiously optimistic on the outlook of our business for the year as the
operating environment continues to evolve.
Dr. R AnanthanarayananManaging Director & CEO
3
Solid execution led to an all-round performance with 132% QoQ growth in EBITDA
Revenues
Gross Margins
EBITDA
Pharma PAT2
Pharma EPS2
₹7,847m ₹6,126m ₹6,888m 26% 14%
Q1FY21 Q4FY20 Q1FY201 QoQ% YoY%
₹4,825m ₹3,750m ₹3,726m 29% 29%
₹1,578m ₹680m ₹1,239m 132% 27%
₹788m ₹84m ₹523m 839% 51%
₹8.8 ₹0.9 ₹5.8 839% 51%
60.3% 54.1% 120 bps 740 bps
10.9% 18.0% 920 bps 210 bps
61.5%
20.1%
1. Includes Ranitidine sales of ₹443m in Q1FY20 2. Pharma PAT and Pharma EPS for Q1 FY21 excludes Exceptional items gain of ₹445m and Biotech and CHC share of loss of ₹201m
4
Regulated market traction continues along with an improved emerging markets performance
Market Q1FY21 Q4FY20 Q1FY20 QoQ% YoY%
US 3,738 2,931 3,4591 28% 8%
Other Reg 2,606 2,260 1,705 15% 53%
Total 6,344 5,191 5,164 22% 23%
1. Adjusted for Ranitidine, the Q1FY20 US revenue including sales of Ranitidine was ₹3902. YoY and QoQ growth are on INR reported numbers
Total 7,847 6,126 64451 26% 22%
Regulated Markets
Emerging Markets
Market Q1FY21 Q4FY20 Q1FY20 QoQ% YoY%
Inst. Biz 810 625 880 30% -8%
Africa 693 400 401 73% 73%
Total 1,503 1,025 1,281 47% 17%
Consolidated Group Revenues
Key Highlights
Regulated Markets
US
• US reported ₹3,738m revenues($50m), up by 28% QoQ and 8% YoY
• Strides delivered a healthy business outcome despite Covid-19 related headwinds in the market
• Market share for key base products and recent new launches remains steady
Other Regulated Markets
• Other regulated markets grew 53% YoY and 15% QoQ reporting its highest ever quarterly
revenues of ₹2,606m ($35m)
• Performance was driven by the key front-end and partnered markets of UK , Germany, Australia,
Nordics and Netherlands
Emerging Markets
• Post a tepid performance in FY20, the emerging markets have turned the corner and have shown
signs of improvement
• Africa grew 73% YoY and QoQ, driven by the key brands and improvement in primary sales inline
with secondary sales
• The Institutional business achieved a 30% growth over Q4FY20, factoring a higher order pick up
by the donor funds.
• During the quarter, we received WHO PQ approval for TLD, a key ARV product
R&D
• The R&D spend in Q1FY21 was ₹247m.
• Filed 2 ANDAs and received approval for 3 new ANDAs. In the other regulated markets, filed 4
products and received 2 new product approvals
5
Strides remains optimistic to continue the scale up in the regulated market
Strides Regulated Markets
₹6,344m ₹5,191m ₹5,164m 22% 23%
Q1FY21 Q4FY20 Q1FY20 QoQ% YoY%
$85m $73m $73m 16% 16%
Growth Drivers Near Term Challenges Outlook
• Continued traction in the US Business
driven by steady base busines and new
launches during the year
• Portfolio fungibility driving the overall
product and market penetration in the
other regulated markets
• Challenges around COVID 19 continues
to have an overhang on the front-end
markets
• Softness in demand led by lower
prescription rates, decline in elective
surgical procedures and lower footfall
at pharmacies
• Strides remains optimistic of achieving
its business outlook in the regulated
markets for FY21
• We expect the growth to continue in
the ongoing year as we unfold a large
pipeline of approved products with
market fungibility across our operations
6
Strong comeback quarter in the US, business reports industry leading 28% QoQ growth
Q U A R T E R O N Q U A R T E R Y E A R O N Y E A R
$49$50
$41
$50
• Strides reported a strong Q1 FY 20 performance in the US
markets despite ranitidine withdrawal
• Business reported a 28% QoQ growth to $50m revenues in
Q1FY21
• During the quarter launched 2 new products, product launch
momentum to continue
• Base business continues to maintain its market share as we
ensured continuity of supplies through superior supply chain
execution amidst the Covid-19 temporary disruptions
• Received 3 ANDA approvals, products will be launched in the
coming quarters
• Continued focus on maintaining supply continuity and high
level of customer engagement
Financial Performance (₹/$M) Performance Updates
28%QoQ
8%YoY
1. Adjusted for Ranitidine, the Q1FY20 US revenue including sales of Ranitidine was ₹3902.
YoY and QoQ growth are on INR reported numbers
₹ 3
,45
9
₹ 3
,73
8
Q1FY20 Q1FY21
₹ 2
,93
1
₹ 3
,73
8
Q4FY20 Q1FY21
7
Other regulated market continues to scale, reports 53% YoY growth
• The other regulated markets reported 53% YoY and 15%
QoQ growth to achieve its highest ever quarterly run-rate.
• The business has achieved $35m scale with improvement in
the margins due to operating leverage
• Strong growth continues in the other regulated markets
although the market remains sluggish at the pharmacy level.
• Increase in the supplies to Arrotex in Australia with healthy
order book visibility
• Business remains healthy due to product launches, increased
market shares and portfolio cross-pollination
• We continue to invest in R&D to expand our portfolio for
other regulated markets. During the quarter, we filed 4 new
products and received 2 approvals
Performance Updates
Q U A R T E R O N Q U A R T E R Y E A R O N Y E A R
Financial Performance (₹/$M)
15%QoQ
53%YoY
₹ 1
,70
5
₹ 2
,60
6
Q1FY20 Q1FY21
₹ 2
,26
0
₹ 2
,60
6
Q4FY20 Q1FY21
$24
$35
$32
$35
YoY and QoQ growth are on INR reported numbers
8
Emerging markets sees green shoots in the performance, reports a 47% QoQ growth
• The Emerging market business picked up sequentially,
reported $20m revenues in Q1FY21
• Post the strategic reset, the brands Africa business reported
an improvement in the performance driven across all
indicators. While Q1 FY 21 has been a strong comeback
quarter for Africa business, we are seeing softness in acute
therapies due to lower prescription rates
• Our Institutional business performance was on track. We
have now received WHO PQ approval for TLD. The product is
undergoing country specific registrations and will be available
for the commercial launch in H2FY21
• TLD commands a significant share of the donor funding
pool as the product has been included as a preferred first-
line option among the current antiretroviral drug
regimens
• Our WHO approved manufacturing facility in Kenya had a
steady quarter. We continue to build on our “In Africa for
Africa” strategy through local manufacturing of products for
the markets
Performance Updates
Q U A R T E R O N Q U A R T E R Y E A R O N Y E A R
Financial Performance (₹/$M)
47%QoQ
17%YoY
₹ 1
,28
1
₹ 1
,50
3
Q1FY20 Q1FY21
₹ 1
,02
5
₹ 1
,50
3
Q4FY20 Q1FY21
$18$20
$14
$20
YoY and QoQ growth are on INR reported numbers
9
Puducherry Facility reclassification status
The USFDA inspected our Puducherry site from January 28, 2019, to February 5, 2019. The site
was classified as Official Action Indicated(OAI) followed by a warning letter in July 2019.
We have completed and submitted all Corrective and Preventive Action (CAPA) plans,
verified by the external third-party remediation agency
We are awaiting the re-inspection of the facility which has got delayed due to Covid-19
disruption
We continue to engage with the agency on the reclassification and shall update outcomes when
available
10
Amidst the Covid-19 uncertainties, Strides remains cautiously optimistic of its FY21 outcomes
F Y 2 1 O U T L O O K
• Q1 FY21 has been a strong comeback quarter
for Strides despite Ranitidine withdrawal
• We believe given the current scenario,
challenges around COVID 19 will continue to
have an overhang on the industry including
• Softness in demand led by lower
prescription rates, decline in elective
surgical procedures and lower footfall
at pharmacies
• Unforeseen challenges in supply chain
• Increase in operating cost including
higher logistics cost
• Strides is cautiously optimistic on the overall
business outlook for FY21
PEOPLE FIRST
BU
SI
NE
SS
C
ON
TI
NU
IT
Y
ME
AS
UR
ES
o Established leadership connect globally and ensure employee Safety & Wellbeing
o Build Emotional Connect through multiple channels – extending to families of employees
o Rapid response & agile adaption of new work practices at organization level globally
BUSINESS ENGAGEMENT
o Right size channel inventory to avoid stock out situations given constraints
o Strengthen customer advocacy by adhering to supply commitments, build a strong
connect with customers leveraging digital platforms
o Focus on improving productivity and efficiency at each level to maximize returns
FINANCIAL FOCUS
o Drive business performance to achieve plan targets and cost management programs
o High focus on Enterprise Risk Management framework
o Austerity measures to contain cost and preserve cash without disrupting business
o No major new investments or M&As until we have better visibility on situation
OPERATIONS & SUPPLY CHAIN CONTINUITY
o Proactive engagement with suppliers to ensure uninterrupted supplies of materials
o Smart working capital management
o Continued compliance of all sites with focus on sustaining and maintaining the quality
metrics
11
Update on Biotech and other investments
Stelis Biopharma- Operations expected to break even in FY22
Foray into Sterile Injectables
• Biosimilar PTH (Teriparatide) targeting
Osteoporosis with < 4 global competitors
• EU filing in Q2FY21, US dossier
submission under 505(b)(2) in FY22
• Product already partnered in EU and
key emerging markets
• Licensed to Strides for front ending
the opportunity in the US
• Disrupting high volume insulin and analogs
space with our low-cost technology
• Development on track, technology
validated in Insulin Glargine; Lispro and
rh-Insulin
• Phase 1 trials for Glargine to commence
in Q2FY21
• Fully integrated, multi-capable facilities and
skill sets for end-to-end biopharmaceutical
development and manufacturing needs for
customers
• Comprehensive services to support all phases
of pre-clinical and clinical development
• CGMP manufacturing of Drug Substance and
Drug Product for commercial supply for both
microbial & mammalian biologicals
• 3 Drug product line suites on stream with 5+
partners on board
• Microbial drug substance suite going on
stream with ongoing validations
• Mammalian drug substance suite to be up
and running from April 2021, delayed due to
Covid-19 related travel restrictions
• Commissioning a state-of-the-art vaccine suite
for multiple vaccine types , going on stream
from December 2020
• High speed filling lines with yearly capacity of
60 million vaccines and 25 Million for
Lyophilised vaccines
• Can cater to vaccine types including Viral
vector, Protein subunit, RNA and DNA
• Discussions ongoing with global companies
developing vaccines for Covid-19
Biopharma (Follow on Biologics) BioSource(CDMO services) Vaccines(New Pivot for growth)
• Strides on September 20, 2019, announced that it would re-enter into sterile injectables business post the completion of the Company’s non-compete period with
Mylan Inc. which ended in December 2019.
• The investments were planned for a global foray in Sterile injectables leveraging the group’s rich experience in the domain.
• Given the unprecedented developments due to Ranitidine product withdrawal and Covid-19 outbreak, the Company has put on hold all the new investments. As
the injectable business is long gestation in nature, the Company will review its decision on investments. Meanwhile, the promoters of the Company continue to stay
invested in injectables and Strides retains an option until December 2020 to participate in the existing platform
Strides committed to invest $40m into Stelis for a majority stake in the biotech business, ~$15m from the same has already been invested
Financial Performance
13
Robust cash generation resulted in Pharma Net debt reduction by ₹1,285m
Pharma Net Debt
As at March 2020
₹ 6,953m
As at June 2020
₹ 5,668m
Change over previous quarter
-₹1,285m
Investments in CHC & Biotech
As at March 2020
₹ 4,516m
As at June 2020
₹ 5,049m
Change over previous quarter
₹533m
Total Net Debt
As at March 2020
₹ 11,469m
As at June 2020
₹ 10,717m
Change over previous quarter
-₹752m
Pharma ROCE%
For FY20
10.8%
For Q1 FY21
13.2%
Increase over FY20
240bps
Pharma Net debt represents Net debt, minus Cash investments made in Biotech and CHC business
14
Operating leverage continues, delivering strong margins
Revenues (₹M) Gross Margins(%) EBITDA(%)
₹ 4
,76
8
₹ 5
,24
0 ₹ 5
,73
8
₹ 6
,18
7
₹ 6
,88
8
₹ 7
,18
0
₹ 7
,35
3
₹ 6
,21
6
₹ 7
,84
7
Q1'19 Q2'19 Q3'19 Q4'19 Q1'20 Q2'20 Q3'20 Q4'20 Q1'21
46
.2 50
.4
51
.2 53
.4
54
.1
58
.4
64
.5
60
.3
61
.5
Q1'19 Q2'19 Q3'19 Q4'19 Q1'20 Q2'20 Q3'20 Q4'20 Q1'21
10
.2
9.3 1
1.3
15
.4
18
.0
21
.0
25
.2
10
.9
20
.1
Q1'19 Q2'19 Q3'19 Q4'19 Q1'20 Q2'20 Q3'20 Q4'20 Q1'21
Q4FY20 impacted on account of Ranitidine withdrawal.
15
Q1FY21 delivers a strong overall performance
Particulars Q1 FY21 Q1 FY20 YoY Q4 FY20 QoQ
Revenues 7,847 6,888 14% 6,216 26%
EBITDA 1,578 1,239 27% 680 132%
EBITDA % 20.1% 18.0% 210bps 10.9% 920bps
Pharma PAT1 788 523 84
Pharma EPS1 8.8 5.8 0.9
Income statement (₹m)
Reconciliation of EBITDA (₹m)
As per SEBI results Q1 FY21 Q1 FY20 Q4 FY20
Profit before exceptional items & tax 811 529 -30
Less: Interest, Dividend income 94 73 147
Add : Depreciation and Amortization 491 429 453
Add : Finance costs 369 353 403
Consolidated EBITDA as per press note 1,578 1,239 680
1. Pharma PAT and Pharma EPS for Q1 FY21 excludes Exceptional items gain of ₹445m and Biotech and CHC share of loss of ₹201m
16
Pre-register and join without operator
Join through an operator using dial in numbers
24-hour playback after the call
Strides Pharma Science Ltd – Q1FY21 Earnings Call
invites you to interact with the senior management on
Q1FY21 earnings on
Speakers:
Arun Kumar
Founder & Non -
Executive Chairman
Badree Komandur
Executive Director &
CFO
Dr. R. Ananthanarayanan
Managing Director &
CEO
WEDNESDAY, AUGUST 5, 20205:15pm IST / 12:45pm BST / 07:45am EDT / 07:45pm HKT
Click here
India Primary +912262801434 / +912271158838
All other regions +91-7045671221
USA 18667462133
UK 08081011573
Singapore 8001012045
Hongkong 800964448
+91 22 71945757 / +91 22 66635757
Playback Code: 66741
Thank you
Strides Pharma Science LimitedCIN: L24230MH1990PLC057062
Regd. Office: 201, ‘Devavrata’, Sector - 17, Vashi, Navi Mumbai - 400 703
Corp. Office: Strides House, Bannerghatta Road, Bangalore – 560076
Investor RelationsSandeep Baid: [email protected]
Corporate Communication Dr. Usha Iyer: [email protected]
BSR&Co.LLPChartered Accountants
Limited Review Report
ToBoard of Directors of Strides Pharma Science LimÍted
l. We have reviewed the accompanying Statement of unaudited consolidated financial results ofStrides Pharma Science Limited ("the Parent") and its subsidiaries (the Parent and its subsidiariestogether referred to as "the Group"), and its share of the net loss after tax and total comprehensiveloss of its associates and joint ventures for the quarter ended 30 June 2A20 (the Statement"),being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (ListingObligations and Disclosure Requirements) Regulations, 20L5, as amended ('ListingRegulations').
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent'sBoard of Directors, has beenprepared in accordance with the recognition and measurement principleslaid down in Indian Accounting Standard 34 *Interim Financial Reporting!'("Ind AS 34"),prescribed under Section 133 of the Companies Act,20L3, and other accounting principles generallyaccepted in India and in compliance with Regulation 33 of the Listing Regulations. Ourresponsibility is to express a conclusion on the Statement based on our review.
3" We conducted our review of the Statement in accordance with the Standard on Review Engagements(SRE) 2410 "Review of Interím Financial Information Pedormed by the Independent Auditor ofthe Entity", issued by the Institute of Chartered Accountants of India. A review of interim financialinformation consists of making inquiries, primarily ofpersons responsible for financial and accountingmatters, and applying anaþical and other review procedures. A review is substantially less in scopethan an audit conducted in accordance with Standards on Auditing and consequently does not enable usto obtain assurance that we would become aware of all significant matters that might be identifiedin an audit. Accordingly, we do not express anaudit opinion.
We also performed procedures in accordance with the circular issued by the SEBI under Regulation33 (8) of the Listing Regulations, to the extent applicable.
4. The Statement includes the results of the entities mentioned in Annexure I of this limited reviewreport.
5. Attention is drawn to the fact that the figures for the 3 months ended 3l March 2020 as reported inthese financial results are the balancing figures between audited figures in respect of the full previousfinancial year and the published year to date figures up to the third quarter ofthe previous financialyear. The figures up to the end of the third quarter of previous financial year had only been reviewedand not subjected to audit.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based onthe consideration of the review reports ofother auditorsreferredtoinparagraphTbelow,nothinghascome to our attention that causes us to believe that the accompanying Statement, prepared in accordancewith the recognition and measurement principles laid down in the aforesaid Indian AccountingStandard and other accounting principles generally accepted in India, has not disclosed the informationrequired to be disclosed in terms of Regulation 33 of the Listing Regulations, including the mannerin which it is to be disclosed, or that it contains any material misstatement.
Embassy Goll Lirrks Business ParkPebble Beach, B Block,3rd FloorOff lntermediate Ring RoadBengaluru 560 071 lndia
B S R & Co. (a pannership fìrm withñôg¡6iråtion No. BAg1223l conv€rtod inloB S R & Co. LLP (d Limitôd Liab¡lity Pârtnôrshipwith LLP Rog¡stration No. AA&8181)with eflect from Octobor 14. 2013
Telephone +91 B0 4682 3000Fax +91 B0 4682 3999
Roglrtcrsd Olllc.36rh Flq, lpdñ¡ ÊplusApdþ M¡lls CÁmpouûdN M J6hi Mtrg, Mlh¡lômìiMumbii 400 0'11
BSR&Co.LLP
Strides Pharma Science Limited
Limited Review report (continued)
7. We did not review the financial information of 5 subsidiaries included in the Statement, whose financialinformation reflect total revenues of Rs. 6,314 million, total net profit after tax of Rs. 1,603 million andtotal comprehensive income of Rs. 1,582 lakhs, for the quarter ended 30 June 2020, as considered in theconsolidated unaudited financial results. The consolidated unaudited financial results also includes theGroup's share of net loss after tax of Rs. 201 million and total comprehensive loss of Rs. 201 millionfor the quarter ended 30 June 2020, as considered in the Statement, in respect of 4 associates, whosefinancial information have not been reviewed by us. These financial information have been reviewed byother auditors whose reports have been fi.¡mished to us by the management and our conclusion on theStatement, in so far as it relates to the amounts and disclosures included in respect of these subsidiariesand associates, is based solely on the reports of the other auditors and the procedures performed by usas stated in paragraph 3 above.
Our conclusion on the Statement is not modified in respect of the above matters.
8. The Statement includes the financial information of 37 subsidiaries which have not been reviewed,whose financial information reflect total revenue of Rs. 1,056 million, total net loss after taxof Rs.266 million and total comprehensive loss of Rs. 266 million for the quarter ended 30 June 2020, asconsidered in the Statement. The Statement also includes the Group's share of net loss after tax ofRs. 9 million and total comprehensive loss of Rs. 9 million for the quarter ended 30 June 2020, asconsidered in the consolidated unaudited financial results, in respect of 5 associates and a jointventure, based on their financial information which have not been reviewed. According to theinformation and explanations given to us by the management, these fìnancial information are notmaterial to the Group.
Our conclusion on the Statement is not modified in respect of the above matter.
þrBSR&Co.LLPCharteredAccountantsFirm's Registration No: 1 0 I 248WTV-1 00022
Sampad Guha ThakurtaPartnerMembership No. 060573UDIN: 20060573 AAA Aì-r48998
Place: BengaluruDate: 5 August 2020
BSR&Co.LLP
Strides Pharma Science Limited
Annexure I to the audit report
Sl. No. Entity and the country of incorporation1 Altima Innovations Inc., United States
2 Apollo Life Sciences Holding Proprietary Limited, South Africa3 Aponia Laboratories Inc, United States
4 Arrow Life Sciences (Malaysia) SDN BHD, Malaysia
5 Arrow Pharma (Private) Limited, Sri Lanka
6 Arrow Pharma Life Inc., Philippines
7 Arrow Pharma Pte Limited, Singapore
8 Arrow Remedies Private Limited, India
9 Beltapharm SPA,Italy10 ERIS Pharma GmbH, Germany
il Fagris Medica Private Limited, IndiaT2 Fairmed Healthcare AG, Switzerland13 Fair-Med Healthcare GmbH, Germany
t4 Generic Partners (Canada) Inc, Canada
15 Generic Partners (International) Pte Limited, Singapore
t6 Generic Partners (R&D) Pte Ltd., Singapore
t7 Generic Partners UK Limited, United Kingdom18 Regional Bio Equivalence Centre S.C, EthiopiaL9 Shasun Pharma Solutions Inc., United States
20 Stabilis Pharma Inc., United States
2I Stelis Biopharma (Malaysia) SDN. BHD., Malaysia
22 Stelis Biopharma Private Limited, India23 Strides Arcolab International Limited, United Kingdom24 Strides CIS Limited, Cyprus
25 Strides Consumer Private Limited, India26 Strides Emerging Markets Limited, India27 Strides Foundation Trust, India28 Strides Global Consumer Healthcare Limited, United Kingdom29 Strides Life Sciences Limited, Nigeria30 Strides Pharma (Cyprus) Limited, Cyprus
3t Strides Pharma (SA) Pty Limited, South Africa32 Strides Pharma Asia Pte Limited, Singapore
33 Strides Pharma Canada Inc, Canada
34 Strides Pharma Global (UK) Limited, United Kingdom35 Strides Pharma Global Fte Limited, Singapore
36 Strides Pharma Inc., United States
37 Strides Pharma International Limited, Cyprus
38 Strides Pharma Science Limited, India39 Strides Pharma Science Pty Limited, Australia
440 Strides Pharma LIK Limited, United Kingdom
l4t Strides Shasun Latina, SA de CV, Mexico
442 Strides Vivimed Pte Limited, Singaporet43 SVADS Holdings SA, Switzerland
BSR&Co.LLP
Strides Pharma Science Limited
Annexure I to the audit report
Sl. No. Entity and the country of incorporation44 Trinity Pharma Proprietary Limited, South Africa45 Universal Corporation Limited, Kenya
46 Vivimed Life Sciences Private Limited, India
47 Arco Lab Private Limited, India48 Strides Consumer LLC.49 Stelis Pte Ltd, Singapore
50 Vensun Pharmaeuticals Inc, USA51 Pharmapar Inc, Canada
52 Juno OTC Inc. , Canada
53 Strides Netherlands BV54 Sihuan Strides (HK) Limited, HK55 Stelis Biopharma LLC, USA56 Strides Nordic ApS
Previous yeorended
Mqrch 31.2020
AUDITED
f4)
1C,243 ¿?
i.469 43
i448.: '')
¿ ¿: \ :,r.
't 737.i2
o.JZ¿ NU
25.654.95
2.3?5.89
177 ó.8c)
¡,ót 9.09
lt,472.29154ó-80
27 ,519 71
28,050.84
{r84 ró)
122.44
ó5.89
(127.61)
305-9ó
(r óó.84)
I 13.23
433.57
Conespond¡ng 3Monlhs ended inthe previous yeor
June 30.2019
UNAUDITED
(s)
3.091.ó r
JãZ.JJ
i3rs 40)
971.25
353.40
428.91
1.492.14
26.94
ó.¿t3l . t 4
529.38
16ó.4ól462.92
( r 78.08)
284.84
(r s8.se)
29.12
65.A9
(224.48)
ì 55.04
(r 23.80)
31.24
253.ó0
6,857.99
6.960.52
Preced¡ng 3 Monlhsended
Morch 31,2020
AIJDIfED
(21
1,756.61
3ó3.40
346.52
),240.9C
403.27
453.40
1 .642.'t i
tðô.52
6,392.73
(2?.781
t1.7ja.eel11,730.77l
(447.8o]|
(2.178.s71
8.24
8.24
(2,O6s.66)
6.186.44
176.51
6,362.95
lt 16.79)
12.12
(104.67)
(2,O7s.?O)
3 Monlhsended
June 30. 2020
UNAUDITED
nl
2.7 66.9 d
44439¡\l84.78)
".297 .83
3ó9. I 0
4?l.32
i.987.48
i38.e3j7,12935
81 t.ó7
449.1.8
¡,260.85
{20e.ó0ìI ,05r.25
1,O1A-42
ó8.t0
í3s.27].
32.83
r,018.42
7.81 7.97
;23 C5
/ .941.O2
Particulors
Expenses
icl Cosi Õr Toter¡ols coñsumedlbl Pe.ç1q565 of siock-in-lrode(cl Chcnges in inventories of flnished gcocs work-ìn-cfogress ond stock-;n-trode
{oj inrpioyee beneñÍs expense
(e) Finonce cosis
{i} Deprecioiion ond omortisolion expense
fg) Other expenses
(h) Foreign exchonge fgoin) / loss - ne;
Tolol expenses (lV)
Profii / (loss) before exceplionol ilems ond tox (lll - lV)
Êxcepiìonol ¡lem: - nei goin / iloss) ÍRefer roi. 7l
Profif / (loss) before lox (v + vl)
Shore of loss of joinl venfures ond ossocioi=s
Profrt/ (loss) before tox (Vll + Vlll)
lox expense
- Current lox
- Deferreci lox
Totol tox expense (X)
Profrt / (loss) ofter tox from conlinu¡ng operolions (lX - X)
Disconlinued operolions
- Prolit | {lossJ from disconlinued operoiions- Goin on disposol of ossefs / selllemeni oi liobiiities ottributoble io Ihe dìscontinued operoiions (nel)
- Tox expense / fbenefill of discontinued ope:qlic'ìsProfit/(loss) ofter lox from discontinued operolionsProfil / (loss) for lhe period (Xl + XllD
Continuing operotions
Revenue ircm operotìons
O{5er rncorne
Totol income (l + ll)
.!*' '":,\^i.1. ,è
STRIDES PHARMA SCIENCE TIMITEDClÌ\¡: L2423CMIì i?93Þ rC.a57C6Z
Regd. Office: No. 201 Devovroto, Secfor Ì7, Voshi, Novi Mumboi 400 703.
Cc'a' ()rriae S1;:cies -rlse, 3iie<oholli 3:rr.e'glcrlio Rooci. SolgÕiore-¿oi: JlcSTATEMENT OF CONSOTIDATED UNAUDITED RESUI.IS
TOR IHE QUARTER ENDED JUNE 30,2O2O
Rs. in Milion
Strides
st.
No.
xtxil
xlIxrv
x
v
vilvilt
lx
il
ilt
lv
Previous yeorended
Morch 31,2020
AUDITED
(4)
1147 .24"
Õ.J:
329 8.C
.79 .82
370.70
676.66
3ó3 9'
lsT esl
305.9ó
t7.82)378 52
370.70
7 42.43
t\65.77)
676.66
I
I
.özl
.62j
5.ó8
5.ó8
4.06
4.06
Correspond¡ng 3
Monlhs ended inthe previous yeor
June 30. 20 1 9
UNAUDITED
(s)
(80. ì 2)
130s.82)
7.7C
(378.241
(349. r 2)
17 e3l2?.12
i37O.s2)
{378.24)
i333.47)
{rs ós)
(34e.r21
0.4ì
0.41
3.t ì
3.1I
(2.70)
12.7o)
(r.943.8ó)
0.09
0.09
122.86]'
(22.8s)
122.77)
122.76)
Preceding 3 Monihsended
Morch 31 2020
(21
t 21.80
(¡.e43.8ó)
(2.0ó5.6ó)
124.64
(2.801
r2r.80
(1..9i 4.66]
l2e.2a)
l t.5ó
I t.5ó
i r.5ó
I r.5ó
3 Monihsended
June 30. 2020
AUD¡TEDUNAUDITED i
(1)
r8ó.89
!?o a? I
283.93
'\59.22j
(4s. ì 0)
8.30
144.$371.77
'ì.390.19
22
035.ó¿ (2.03e.26)
126.4c)
1.O18.42
37 t .5ó
a.2l371.77
{i7.01)i,390. t 9
Poriiculors
Oiher comprehensive income
{i) liems tnoi w¡¡i noi be reclossifieo ¡o siorerneni oi oroíii ono ioss
(ii) l"come icx relciing io items thcl \e ll .c+ be reciosslfied :c sic:emen' cf profit ond loss
{ì} ltems :hot rnoy be reclossified;o s:oie:¡eni oÍ oroiii ono loss
(ji) inccne Ìcx reloiìng 1o iìems ihoi mcy oe reclossified 'ic sicleme¡î of prcfii ond ioss
Tolol other comprehensive income for the period (XV)
Totol comprehensive ¡ncome for the period (XlV + XV)
Profit for lhe period othibutoble to:
- Cwn€¡s cf the Ccmpony- Non-conlrolling inieresfs
Eornings per equity shore (foce volue of Rs. l0/- eoch) (for conlinuing operotions)
{l)Bosic (in Rs.)
(2) Diluîed {ìn Rs.)
Eornings per equily shqre (foce volue of Rs. l0/- eoch) (for disconiinued operolions)
{1} Bosic {in Rs.)
(2) Diluted {in Rs.)
Eornings per equity shore (foce volue of Rs. I 0/- eoch) (for lolol operolions)
.-------'"/
\,í-
Çtr
Other comprehensive income for the period
- CwneÍs cf ihe Comoony
- Non-ccntroilìng inlerests
Totol comprehensive income for the period
- Owners of ihe Compony- Non-controllìng inlerests
{l ) Bosic (in Rs.}
(2) Diluted (in Rs.)
see occomponying notes lo the tinonciol Results
.I " 'i , STRIDES PHARMA SCIENCE TIMITEDCIN: L2a230MH I 99CP:CC5'Có2
Regd. Office: No. 201 Devovrolo, Sector 17. Vosiri, Novi Mumbo¡ 4O0 703.
Cotp. Office: \'- cjss -oJse", Bìlekc¡cll:. 3c. -3.9..'r. R.r:c A()rgclc-.----<: i C/ó
SIATEMENÌ OÍ CONSOTIDATED UNAUDITED RESUTTS
TOR THE QUARTER ENDED JUNE 30,2O2A
Rs. in Milion
Strides
51.
No.
xvt
A
B
XV
Previous yeorended
Morch 31, 2020
AUDITED
2,304.97
2.374.99
(6ó.02)
lrr3.r7)(r7e.re)
14.e7)
(r 84. r ó)
122.44
ó5.89
('t27.61)
Correspond¡ng 3Monlhs ended inlhe previous yeor
June 30.20i9
UNAUDITED
2,3A4.97
2.345.42
(40.45)
{ri3.r7)(r53.ó2)
{a971
(rs8-5e)
65.89
e24.4e)
Preceding 3 Monlhsended
Morch 31.2020
AUDITED
8.24
3 Monlhsended
June 30,2020
UNAUDITED
PorTiculors
Totol Expenses
Profit/(loss) belore exceplionol items ond tox (l - ll)Excepfionol ilems
Profit/(loss) before tox (lll + lV)
Shore of profìl / {loss} of joìni veniures ond ossocìoles
Profil/(loss) before lox (V + Vl)
Goìn / {loss} on disposols (neT)
Tox expense / {benefit)Profif/(loss) from disconlinued operolions (Vll+ Vlll - lX)
otol Revenue
l_, o
sl.No.
I
il
ilt
v
vilviltIX
x
principles geneicily occepted in Indio cnd rn lerrns of Regulotion 33 cf the SEBl {LisIing Obligotio|s cno Disclosure Requirementsi Regulof¡ons,20l5.
revieweC lhe resulis tor 1!re cuorTer enCeC Ju¡e 3C.2A2A ond hove issued on unmodiÍied coinicn.
such chonge, oll comporoiìve numbe:s ncve been presented in lndion Rupees millìons onC hcve ceen rounCecl off to iwo decimol ploces
{net)" onci is oreseniecj os porf of discor.iir¡eo operotìons.
periods) ore oìsciosed in fhe tobie below:
Rs. in Million
Noles:
.#'rL"..íþ" '!#,-#ê:". ;;.3
STRIDES PHARMA SCIENCE TIMITEDCIN: 124230M1-i I 99CÞLCû57Có2
Regd. Office: No. 201 Devovrolo, Secior 'ì7, Voshi, Novi Mumbo¡ 400 703.
Ccrp. CÍiice: "S;rìdes -ir¡-se 3ilekoholli. 3o:re¡g¡olio Rooc. Sorgoiore-SóO C7ó.
STATEMENT OF CONSOTIDATED UNAUDITED RESUI.TS
FOR THE QUARTER ENDED JUNE 30.2O2O
Strides
+ *
AUDITED
1s47 99)
(r,r3r.r2)
{9¿.89)
\42.64\1
ì.0¿3.58
Previous yeorended
Morch 31,2020
(22.38)
{r7.ró)(26.e2)
Corresponding 3
Monihs ended infhe previous yeor
June 30, 2019
UNAUDITED
(r.700.99)
AUDITED
fì.r3r.r2i
{s94 r3)
{7 ss)
35 59
Preceding 3 Monihsended
Morch 31. 2020
449_ t 8
UNAUDITED
528.70
{84.83)
25.30
{0.04)(r e.es)
3 Monihsended
June 30,2020
Êxchonge oo¡n.i {iossJ on long-term foreign currencyinirc-grcup locns
- Wrile down of rrvenTory ond other expenses on occounT of Roniiiciine withcirowol (refer note ó)
lmpoir.'nenr of GooowillFoir voluotìon goin on ocquìsilion of conlrollìng shores in Foirmeci l-reoilhcore { Refer nole 5}
Business ccr¡oì.c+icn ond restructuring expenses
nding/ concellotìon of gross obligolions ond contingent consìderoUoniRefer nole 8)
loons, derivoiives. oeferreci considerolìon ond
Foir voluoTìon of derivotive insiruments
Porticulors
Sioiemeni of Profii ond Loss under exceptìonol ifems.
'loConsequently
reversedbeenKenyo.
hosmiied.lion
Li
mil9,092.Rs.
Corporotìonioiing
Unìversolofomoune)
49%)
ndinnierestng
bsequentSU
non-conirolliluding{inc
ocquire1o
ptionoputopiionuip'ihe
oforesoidder'ine
UN
ndeiUisifionobligotionlhe
ocquofiimeconcelled
theoihosGroup
occruedlhe
liobilityyeororevrcus
bligolionoÌhe
grosstheDuring
5 During ihe quor.ter.. the G:oup goìned controlling ìnteresT ìn Foirrneci ¡eciThcoie AG, Swiizerlond. ihereby moking ii o subsidiory of lhe group.
in the foir volue of non-controllìng inTeresl held ond cor'rying volue of equity in Foir''ned.
6 Or, Mc:'cn 3'.. 2C2A. US Food ond D
prescripiion {Rx) cnc over-lhe-counlerinrpurity n rc¡;1ìotne ßredicclìons. As
from the moikel
7 Exceplionol ltem goin/ (loss) (nef):Rs. in Million
olofDMA]{Nne
the
w¡ihcirowo
cirowi
ngmethylomi
w'th
uesti
oftosodi
reqNiN.
fcrms
processtheof
thennliyvesligocurreIS
¡gnd
gc'ucl
F¡of
prodtheircn
lheof
foctui'ers
n
boseciulio
monùwosP
cll
distribsleîo
rlherihisfu
ieiter
sed
ss
hos,.nrneoÌclely
;iÞ
e::Cy,.ncrke1
the1e
ofm
zJzl"froDA
9sApri
l, l(;
oruneciì
Inrs
effectìvrcnilì
Aci
(oTc)I'ug
iéWn STRIDES PHARMA SCIENCE LIMITEDCIN: t24230MH 1 990P1-C357Có2
Regd. Office: No. 20.l Devovrqto. Sector '17, Vashi, Nov¡ Mumboi 400 703.
Corp. OJfice: "S1:rcies ro;se . Silekohoii.. 3orne:grcÌlo Rood. Songolo:e-56O C/ó
STATEMENT OF CONSOTIDATED UNAUDIIED RESUTTS
TOR THE QUARTER ENDED JUNE 30, 2O2O
Strides
'!t '. .. \
AUDITED
17.743.'.3
ì5r8.58l I ló.99
Previous yeorended
Morch 3.|,2020
Corresponding 3Monlhs ended infhe previous yeor
June 30,20i9
UNAUDITED
4.656.15
3C3.43
246.88
AUDITED
4.69A.O2
477.63
263.71
Preceding 3 Monthsended
Morch 3i,2020
UNAUDITED
4.246.7)
6't -4O
4't.63
3 Monthsended
June 30, 2020
loîol Revenue from continuing operotions
Profli oefore lox from conlinuing operotions
ProfiT ofler Tox frorn continu¡ng operot¡ons
Profit/{loss) befcre tcx from discontinued operc1'icns
ProfiT/(loss) ofter iox from dìscontinued operotìons
Porliculors
upto the end of the third quorter of the relevonl finonciol yeor, which ore subjecled to limited review.
Direclor & CEO
For ond on beholf of the Boord
Dr. R *Bengoluru,
hove been regrouped ro conform wiih the clossificolion odopled ¡n these finonciol resulfs.
ìl
r2
5, 2020
l3 Previous period figures
STRIDES PHARMA SCIENCE LIMITEDCIN: 124230MH I 990P1CC570ó2
Regd. Office: No. 20.l Devovrolc, Seclor l;' Voshi. Novì Mumboi 400 703.
Co¡o. Oiiice: Sirioes ñouse . òirekchclli, 3cnnerg:,oìlo Roco, 3ongcit.;re-5ó0 0,'ó.
STATEMENT OF CONSOTIDATED UNAUDITED RESULTS
TOR THE QUARTER ENDED JUNE 30,2O2O
oondernic dld not hove ony molerio! ir.rpoct on the fl¡oncio! resu!.ts folihe quorier ended June 30,202C.
ocie io coniinue io generoie suïficienl cosh to meet ils obligolions os they fol! due.
Rs. in Million
StriCes))
9
l0 lnformotion on Slondolone Results : -
Y'
BSR&Co.LLPChartered Accountants
Embassy Golf L¡nks Business ParkPebble Boach. B Block, 3rd FloorOff lntermediate Ring RoadBengaluru 560 O71 lndia
Telephone +91 80 4682 3000Fax +91 80 4682 3999
Limited Review Report
ToBoard of Directors of Strides Pharma Science Limited
1. We have reviewed the accompanying Statement of unaudited standalone financial results of StridesPharma Science Limited ('the Company') for the quarter ended 30 June 2020 ('bhe Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Boardof Directors, has been prepared in accordance with the recognition and measurement principles laiddown in Indian Accounting Standard 34 "Interim Fínancíal Reporting" ("Ind AS 34"), prescribedunder Section 133 of the Companies Act,2013, and other accounting principles generally accepted inIndia and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issuea report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on ReviewEngagements (SRE) 2410 "Revíew of Interim Financiql Informøtíon Perþrmed by the IndependentAuditor of the Entíty " issued by the Institute of Chartered Accountants of India. This standard requiresthat we plan and perform the review to obtain moderate assurance as to whether the Statement is freeof material misstatement. A review is limited primarily to inquiries of company personnel andanalytical procedures applied to financial data and thus provides less assurance than an audit. Wehave not performed an audit and accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2020 as reported inthese financial results are the balancing figures between audited figures in respect ofthe full previousfinancial year and the published year to date figures up to the third quarter ofthe previous financialyear. The figures up to the end of the third quarter of previous financial year had only been reviewedand not subjected to audit.
BSR&Co.LLP
Strides Pharma Science Limited
Limiteel Review Report (continued)
5. Based on our review conducted as above, nothing has come to our attention that causes us to believethat the accompanying Statement, prepared in accordance with applicable accounting standards and otherrecognised accounting practices and policies has not disclosed the information required to be disclosedin terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015 including the manner in which it is to be disclosed, or that it contains anymaterial misstatement.
forBS R& Co. LLPChartered AccountantsFirm's Registration No: 101248WW-100022
Sampad Guha ThakurtaPartnerMembership No: 060573UDIN: 20060573 A\lqÁ4C26633
Place: BengaluruDate: 5 August 2020
Previous yeorended
Morch 3l . 2020
AUDITED
(4)
Corresponding 3 Monlhsended in lhe previous
yeor June 30, 20i 9
UNAUD¡TED
(3)
't,518.58303.40
8.483.3ó
384.ó0
I i.83
2.217.68
667.13
91ó.29
3.391.52
i 52.14
16,224.55
r.518.s8
197.87
203.72
40r.59
t,l tó.99
16.7¿1 .¿9
ì.00r.ó4
17,743.13
92.87
(3ó.31)
5ó.5ó
246-a4
I I ¿.ó3
Í330,q3jcìt co
17,.t8
232.42oì^ <o
4,352.74
303-40
¿,¿,25.32
4,656-14
Preceeding 3 Monlhsended
Morch 31,2020(refer note 8)
AUDITED
(2)
1.9 .a2.56
I t9.55
l2e.2el
ó33.9r
ì83.i8231 .49
928.86
2C2.13
4.212.39
477.63
477.63
(7s.261
289. r 8
213.92
263.71
4.417.41
272.61
4,690.O2
UNAUDITED
(¡)
2.Al3.C7'6', 57
231.94
ó53.591 57.73
237.62
771 94
i7s rs)
4.185-31
óì.40
ót.40
r0.75
9.O2
't9.77
41.63
4,c93.13
ì53.28
4,246.71
Expenses
(o) Ccsi oÍ moTerìols consurned
{o) -'i;cnoses ot srock-in-irooe
{c; Chonges in inveniories of finisheo gooos. work-in-cro!'=ss ond sîock-in-irode
Íd) E.rnployee benefits expense
(e) Finonce costs
(f) Depreciotion ond omortisotion expense
{g) Otcer exoenses
(h) Foreign exchonge (goin)/ loss- nel
Totol expenses (lV)
Profit before exceptionol ilems ond tox (lll - lV)
Exceptionol ltem prof¡T / (loss) (nef )
Prof¡l beiore tox (V + Vl)
Tox expense
- Currenl tox- Defened lox expense/ (benefii)
Tolol lox expense (vlll)Profit for the per¡od (Vll -Vlll)
Cont¡nuing operof¡ons
Reve^ue Í'o:n operoiionsOihei incor.rle
Toloi income (l + ll)
tx
ilt
tv
V
vilvilt
STR¡DES PHARMA SCIENCE LIMITEDCIN: 124230MH t 990PtC0570ó2
Regc. Ciíìce: No. 2Cl Dev:vroio, Secror ì7, ',/oshì, Novi Munrboì 4C0 7C3.
î: ;. 3"'cr. 'S''Ces 1ic:jse". 9le¡.cl:l':. lc:îe:gh'.ji'o ?3oo. 3:rgc:o:e.5ó0 07ó.
S'IATEMENT OF STANDALONE UNAUDITED RESUTTS
FOR THE QUARTER ENDED JUNE 30,2O2O
Rs. in Millíon
Porlic -¡lors
ñ¿ Õ "¡
;3 L f, LL¡.s I'
ü.No.
3 Monthsended
June 30, 2020
+
,.¡@'þq{à} 8@ âa . .t
"'%. ì)frlüestu#
STR¡DES PHARMA SCIENCE TIMITED
CIN: t24230MH I 990P1.C0570ó2
Regd. Off¡ce: No. 20] Devovrolo, Secf or 'ì7, Voshi. Novi Mumboi 4OO 703.
Corp. Office: "Slr¡des House". Bilekoholli, Bonnerghollo Rood. Bongolore-Sóo 07ó.
STATEMEM OF STANDATONE UNAUDITED RESUI.TS
FOR THE QUARTER ENDED JUNE 30,2O2O
Rs. in Million
Previous yeorended
Morch 31, 2020
AUDITED
{4)
(28.e8)
j i.4i(sró.ó0)
ì80.52
(353.ós)
763.34
12.47
t2.47
Corresponding 3 Monlhsended in lhe previous
yeor June 30,2019
UNAUDITED
(3)
29.60
( ì0.43)
19.17
266.O1
2.76
2.75
Preceeding 3 Monthsended
Morch 31,2020(refer nole 8)
AUDITED
(2)
(28.e8)
I t.4l(372.se1
r 30.r9(2se.e7)
3.74
2.94
2.94
3 Monlhsended
June 30, 2020
UNAUDITED
(1)
i75.0ó
t6i.t7lt ¡3.89
ì55.52
o.46
o.46
Porliculors
Other comprehensive income
(i) lTems ihot w¡ll nol be recloss¡fled to stotemeni of profil ond loss
(¡i) lncome tox relofing to ¡tems ThoT will not be recloss¡fied To sÌoTemenT of profil ond loss
(i) llems thol moy be recloss¡fied lo sToTement of profìT ond loss
(i¡) lncome lox reloT¡ng to items thot moy be reclossified to stolement of profit ond loss
Tolol olher comprehensive income for lhe pedod (X)
Tolol comprehensive income for lhe period (lX + X)
Eornings per equity shore (foce volue of Rs. lO/- eoch)
(o) Bos¡c {Rs.)
{b) Diluïed (Rs.}
See occomponying noies lo the F¡nonc¡ol Results
sl.No.
X
A
B
xl
*. striå**STRIDES PHARMA SCIENCE LIMITED
CIN: t24230MH I 990P1C057062Regd. Office: No. 201 Devovrolo, Seclor '17, Voshi, Novi Mumboi 400 703.
Corp. Oífìce: SlriCes ãouse". 3ilekoholli. 30.nergnotlo Rooci, Bongolore-SóO 07ó.STATEMENT OF STANDATONE UNAUDITED RESULTS
IOR THE QUARTER ENDED JUNE 2420Notes:
I Trese finonciol resulTs hove been prepored in occorcionce wiïh Indìon Accounling Stondords {'ìncì AS') prescribed uncier Secîion 133 of ihe Componies Aci, 2013 ond of herprìnciples generolìy occepled in lndio qnd in Terms of Regulolion 33 of the SEBI (Listing Obligoiions ond Disclosure Requirements) Regulolions. 20.l5
resulis for lhe quorter ended June 30,2O2O ond hove issued on unmodified opinion.
Ìo such chonge, oll comporoiive numbers hove been presented in Indion Rupees millions ond hove been rounded off to fwo decimol ploces.
c.ovided.
wìthdrowing ihe producT from The morkef. This wiThdrowol d¡d noi hove ony moteriol impoct on the sloncjolone finoncioì resulls for fhe quorÍer endeci iune 30. 2O2C onci for
crevious yeor ended Mcrch 3l ,202A .Ihe impcci cf ihe withdrowol for ihe group hos been disclosed ìn ihe ccnsolidoted finonciol resulfs.
ó ì" Morch 2O2a, ihe Worlci HeolIh Orgonisolion decloreo COVID- l9 io be o pondemic. The Compony hos ooopteo meosures to curb ihe spreod of inÍeciion in order to proreci
condilions. However, ihe pondemic did nol hove ony moler¡ol irnpoct on lhe finonciol results for the ouorler endecj June 30, 2020.
conlìnue io generole sufficieni cosh io meei iis obligolions os ihey foll due.
ffi srridesSTRIDES PHARMA SCIENCE LIMITED
CIN: t24230MH 1 990PtC057062Regd. Office: No. 201 Devovrqiq, Seclor 17, Voshi, Novi Mumboi 400 703.
Corp. Office:'Slrides House", Bilekoholli. Bonnerghotlo Rood, Bongolore-Só0 07ó.STATEMENT OF STANDAI.ONE UNAUDITED RESUTTS
FOR THE QUARTER ENDED JUNE 30,2O2O
7 The Boord of Directors of fhe Compony on July 29,2019 hove opproved the Scheme of Amolgomotion ('lhe Scheme') uls 23A b 232 of fhe Componies Acf, 2013, between Strides
been ïied wiih Notionol Compony Low Tribunol(NCLT) íor opprovol. The NCLT convened shoreholders rneeiing on Februory 20.2020 ond the merger hos been opproved by the
shoreholciers. The NCLT, Bongolore Bench hos opproveo lhe Scheme vide <¡rder doled Moy 28,2O2O ond the scheme is now pending for opprovol wiih the Mumboi Bench of NCLT-
upîo ihe end of the ihird quorfer oÍ The relevont finonciol yeor, which ore subjected to limited review.
9 Previous period figures hove been regrouped to conform wilh the clossificotion odopted in lhese finonciol resulls-
For ond on beholf of lhe Boord
DfR
Bengoluru, August 5, 20j10 túlonog¡ng Director & CEO
(/)c0
f
+
s Co
